It is associated with indicators of poor prognosis such as lymph node metastasis, poor differentiation, and large tumor size [66,67,68], making COX-2 the most commonly studied anti-inflammatory target in cancer therapy. This evidence concerns the gene PTGS2 and metastatic malignant neoplasm in the lymph nodes.